XNAS
AVLN
Market cap1.54bUSD
Sep 11, Last price
33.57USD
1D
-3.17%
1Q
11.60%
IPO
12.50%
Name
Avalyn Pharma Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0
Net income
-85m
CFO
-81m
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Key people
Lyn Baranowski
Chief Executive Officer
Chief Financial Officer
Mark Surber
Chief Scientific Officer, Founder · since 2022
Nancy Mckinley
Finance, Senior Vice President, Administration
Sofia Ioannidou
Director ( Life Sciences ), Andera Partners
Jonathan Leff
Independent Director, Physician - Scientist · since 2022
David Malek
General Partner, Pivotal Bioventure Partners
Peter Moldt
Partner, Novo Ventures ( Us ), Inc
Niall O'donnell
Managing Director, Managing Director, Rivervest Venture Partners
Stephen Pham
Vice President, Product Development
Ketan Patel
Director
Valuation
Title in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT |